Table 2 Top20 regulated pathways mapped by regulated peptides identified in PBMC proteomes comparing B-ALS versus L-ALS (peptide level). Terms are sorted by adjusted p-values.
From: Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis
PBMCs_Top20 regulated Pathways | Effect size | adj. p-value |
|---|---|---|
Developmental Biology | 0.12 | 6.5E-03 |
Platelet degranulation | 0.12 | 6.5E-03 |
Response to elevated platelet cytosolic Ca2+ | 0.12 | 6.5E-03 |
Regulation of actin cytoskeleton | 0.15 | 7.9E-03 |
Interferon Signaling | −0.49 | 8.6E-03 |
Platelet activation, signaling and aggregation | 0.11 | 8.6E-03 |
Endosomal/Vacuolar pathway | −0.56 | 1.5E-02 |
Interferon alpha/beta signaling | −0.56 | 1.5E-02 |
Interferon gamma signaling | −0.52 | 1.5E-02 |
RHO GTPases activate PKNs | 0.19 | 1.9E-02 |
Caspase Cascade in Apoptosis | −0.18 | 2.7E-02 |
Caspase-mediated cleavage of cytoskeletal proteins | −0.24 | 4.9E-02 |
Systemic lupus erythematosus | 0.31 | 5.3E-02 |
Signaling by Rho GTPases | 0.12 | 6.0E-02 |
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | −0.41 | 6.4E-02 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | −0.70 | 6.7E-02 |
Nef mediated downregulation of MHC class I complex cell surface expression | −0.70 | 6.7E-02 |
Striated Muscle Contraction | −0.20 | 6.7E-02 |
EPHA-mediated growth cone collapse | 0.21 | 6.7E-02 |
RHO GTPase Effectors | 0.12 | 7.9E-02 |
